CTOs on the Move

Harvard Vanguard Medical Associates

www.harvardvanguard.org

 
At Harvard Vanguard Medical Associates, our staff is our most important resource. That's why we offer challenging work, career advancement, competitive salaries and a benefits program that is among the best in the marketplace. The following summary is
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Satori Labs

Satori Labs is a Scotts Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

inVentiv Health

inVentiv Health, Inc. provides value-added services to the pharmaceutical, life sciences, and healthcare industries. The Company operates in four segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. The Company supports a range of clinical development, communications and commercialization activities that are critical to its customers' ability to complete the development of drug products and medical devices and commercialize them. In addition, the Company provides medical cost containment services to payors in its patient outcomes business. inVentiv provides services to over 350 client organizations, including global pharmaceutical companies, emerging and specialty biotechnology companies, and payors.

Austen Riggs Center

Austen Riggs Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Stockbridge, MA. To find more information about Austen Riggs Center, please visit www.austenriggs.net

International Association for Medical Assisance to Travelers

International Association for Medical Assisance to Travelers is a Guelph, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allergen Research

Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.